Nan Fung Group Holdings Ltd
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), Nan Fung Group Holdings Ltd reported 20 stock positions worth $63.4 million. Its top holding was Harmony Biosciences (HRMY) at 18.4% of the portfolio, followed by Illumina (ILMN, 17.9%) and Oculis (OCS, 15.8%). Compared with Q1 2025, it opened 1 new position, sold out of 16 and reduced 1. The biggest buy was a new position in Bolt Projects (BSLK) and the biggest sale an exit from Verona Pharma (VRNA).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $63.4M (Q2 2025)
- SEC Filing
- 0001012975-25-000440 ↗ filed Aug 13, 2025
Holdings Value
Holdings 20 stocks · $63.4M
| HRMY Harmony Biosciences Holdings | 18.37% | 368,665 | $11.6M | No change |
| ILMN Illumina Inc. | 17.93% | 119,196 | $11.4M | No change |
| OCS Oculis Holding AG | 15.75% | 514,702 | $10.0M | No change |
| INCY Incyte Corp. | 6.34% | 59,022 | $4.0M | No change |
| ONC Beone Medicines Ltd.-ADR | 6.00% | 15,722 | $3.8M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 5.66% | 11,872 | $3.6M | No change |
| RXRX Recursion Pharmaceuticals-A | 5.30% | 664,610 | $3.4M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 4.89% | 49,120 | $3.1M | No change |
| ASND Ascendis Pharma A/S | 3.70% | 13,600 | $2.3M | No change |
| LAB Standard Biotools Inc. | 3.56% | 1,883,179 | $2.3M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 3.50% | 102,984 | $2.2M | No change |
| ARGX Argenx SE - ADR | 2.43% | 2,800 | $1.5M | No change |
| KYMR Kymera Therapeutics Inc. | 2.12% | 30,875 | $1.3M | No change |
| RVMD Revolution Medicines Inc. | 1.12% | 19,253 | $708K | No change |
| REPL Replimune Group Inc. | 0.93% | 63,719 | $592K | Reduce -84.6% |
| BCYC Bicycle Therapeutics PLC-ADR | 0.76% | 68,943 | $479K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.53% | 58,347 | $337K | No change |
| TRDA Entrada Therapeutics Inc. | 0.52% | 49,082 | $330K | No change |
| RANI Rani Therapeutics Holdings Class A | 0.40% | 493,584 | $254K | No change |
| BSLK Bolt Projects Holdings Inc. | 0.18% | 40,597 | $114K | New |
Portfolio Sells Q1 2025 → Q2 2025
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −7.66 |
| ZLAB Zai Lab Ltd.-ADR | Sold out | 0.00% | −7.48 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −5.39 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −4.79 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −4.64 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −4.34 |
| MRUS Merus NV | Sold out | 0.00% | −4.12 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −2.82 |
| REPL Replimune Group Inc. | Reduce -84.6% | 0.93% | −2.36 |
| EXEL Exelixis Inc. | Sold out | 0.00% | −1.93 |
| GERN Geron Corp. | Sold out | 0.00% | −1.78 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.45 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.46 |
| DBVT DBV Technologies SA-Spon ADR | Sold out | 0.00% | −0.21 |
| BOLT PROJS HLDGS INC | Sold out | 0.00% | −0.20 |
| AFMDQ Affimed NV | Sold out | 0.00% | −0.02 |
| ALXO Alx Oncology Holdings Inc. | Sold out | 0.00% | −0.02 |
Portfolio Buys Q1 2025 → Q2 2025
| BSLK Bolt Projects Holdings Inc. | New | 0.18% | +0.18 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |